Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Delcath Systems, Inc. - Common Stock (NQ:DCTH)

12.00 -0.20 (-1.64%)
Streaming Delayed Price Updated: 11:48 AM EDT, Apr 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Delcath Systems, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
Eagle Financial Services, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session
Via Benzinga
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Breast Cancer
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host First Quarter 2025 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Analyst Expectations For Delcath Systems's Future
Via Benzinga
Uncovering Potential: Delcath Systems's Earnings Preview
Via Benzinga
Analyst Scoreboard: 4 Ratings For Delcath Systems
Via Benzinga
Delcath Systems Announces Publication of Comparative Analysis from Randomized Portion of FOCUS Study in Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
Beta Bionics Announces Board Appointment of Gerard Michel
From Beta Bionics, Inc.
Via GlobeNewswire
Delcath Systems to Participate at the Canaccord Genuity Horizons in Oncology Virtual Conference
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Reports Fourth Quarter and Full Year 2024 Results
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host Fourth Quarter and Full Year 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Update to National Comprehensive Cancer Network Clinical Practice Guidelines for the Treatment of Metastatic Uveal Melanoma
From Delcath Systems, Inc.
Via Business Wire
Earnings Scheduled For March 6, 2025
Via Benzinga
Delcath Systems to Participate at the BTIG Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2024 Financial Results
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Additional $16.3 Million in Funding From Series E and E1 Warrant Exercises
From Delcath Systems, Inc.
Via Business Wire
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
Why Zoomcar Shares Are Trading Higher By Around 142%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Delcath Systems Announces FDA Clearance of IND Application for Phase 2 Clinical Trial of HEPZATO™ in Liver-Dominant Metastatic Colorectal Cancer
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Reports Third Quarter 2024 Results and Business Highlights
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate in Upcoming Investor Conferences
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Host Third Quarter 2024 Earnings Call
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces Preliminary Third Quarter 2024 Revenue Results
From Delcath Systems, Inc.
Via Business Wire
Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems Announces New Data Presented at ESMO 2024 Demonstrating Efficacy of HEPZATO KIT™ in Metastatic Uveal Melanoma Subgroups
From Delcath Systems, Inc.
Via Business Wire
'This Is A Very Speculative Situation,' Jim Cramer On ADMA Biologics
"Mad Money" host Jim Cramer said, "Any time there's immunity-compromised patients, there's some big money down the road." 
Via Benzinga
Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients
From Delcath Systems, Inc.
Via Business Wire
Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
From Delcath Systems, Inc.
Via Business Wire
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.